Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Approves Asahi Kasei’s Recomodulin Among Others

This article was originally published in PharmAsia News

Executive Summary

Among drugs approved by Japan's Ministry of Health, Labor and Welfare on Jan. 25 is Asahi Kasei Pharma's Recomodulin (recombinant thrombomodulin), the world's first recombinant thrombomodulin drug for treatment of disseminated intravascular coagulation. Other notables are Bayer's kidney cancer drug Nexavar and Zevalin Yttrium IV Set, a monoclonal antibody combined with radioisotope Yttrium, also developed by Bayer



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts